Overview

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Status:
Active, not recruiting

Trial end date:
2023-08-03

Target enrollment:

Participant gender:

Summary

AML is the most common acute leukemia in adults. Most patients can undergo allogeneic stem cell transplantation as a possible cure; however, many patients are not candidates for allogeneic transplant due to age, overall health, psychosocial factors, and/or lack of available donors. Therefore, these patients are unable to receive the therapeutic benefits of the "graft-versus-leukemia" effect of donor immune cells. The aim of this study is to hopefully break immune tolerance to AML cells to provide better outcomes in patients with non-favorable risk AML.

Phase:

Phase 2

Details

Lead Sponsor:

Northside Hospital, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Fludarabine
Fludarabine phosphate
Melphalan
Pembrolizumab